The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.
Approval Alert | Zongertinib in HER2+ Metastatic or Unresectable Nonsquamous NSCLC
Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
Achieving a “Functional Cure” With Multiple Myeloma Therapy
5